Table 1.
Demographic and clinical characteristics of patients
| ad | dlb | p-value | |
|---|---|---|---|
| N | 23 | 19 | – |
| Gender (M:F) | 11:12 | 12:7 | 0.37* |
| Age (yrs) | 78.8 ± 6.0 | 76.2 ± 8.0 | 0.25 |
| MMSE (max. 30) | 17.5 ± 4.8 | 16.2 ± 5.6 | 0.77 |
| CAMCOG (max. 107) | 59.8 ± 15.8 | 63.8 ± 13.9 | 0.40 |
| UPDRS III (max. 108) | 5.8 ± 6.1 | 23.2 ± 13.8 | <0.001 |
| Disease duration (months) | 33.2 ± 18.9 | 33.6 ± 26.0 | 0.96 |
| CAF | 0.3 ± 1.0 | 3.7 ± 3.5 | <0.001 |
| Choice reaction time (CRT) | 6.41 ± 0.23 | 6.93 ± 0.49 | <0.001 |
| Choice reaction time standard deviation (CRT(SD)) | 5.10 ± 0.48 | 5.93 ± 0.74 | <0.001 |
| CHEI use (yes:no) | 2:17 | 5:14 | 0.41* |
| L-dopa or equivalent use (yes:no) | 0:23 | 2:17 | N/A |
Values expressed as (mean ± 1 standard deviation).
*χ2 value (df = 1).
AD = Alzheimer's disease; DLB = dementia with Lewy bodies; MMSE = Mini-Mental State Examination; CAMCOG = Cambridge Cognitive Examination; UPDRS III = Unified Parkinson's Disease Rating Scale (motor subsection); CAF = Clinical assessment of fluctuations; CHEI = cholinesterase inhibitor.
Note that reaction time data (milliseconds) reported have been log transformed.